Introduction:
Delamanid is a nitro-dihydro-imidazo oxazine-class anti-tuberculosis drug that prevents the formation of mycolic acid in bacterial cell walls. It is used as part of a combination regimen to treat tuberculosis (TB) that is both extensively and multiple-drug resistant. Due to the disease's greater death rate and inadequate therapeutic response to typical anti-tuberculosis medicines like Isoniazid and Rifampicin, the emergence of extensively drug-resistant and multidrug-resistant tuberculosis presents clinical concerns for patients. Moreover, second-line treatments with a limited therapeutic index and longer chemotherapy regimens may be necessary for multidrug-resistant tuberculosis.
Delamanid treatment, in combination with the WHO (Wealth Health Organization), recommended optimized background treatment regimen, was linked to better treatment results and a lower mortality rate in clinical research involving patients with pulmonary multidrug-resistant tuberculosis or severely drug-resistant tuberculosis. During treatment, Delamanid resistance developed independently; this resistance resulted from a mutation in one of the F420 coenzymes necessary for Delamanid's bioactivation. Delamanid is marketed as an oral tablet and has received EMA (European Medicines Agency) approval.
For Patients:
Why Is Delamanid Prescribed?
Delamanid is indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB). It is used to treat lung tuberculosis caused by bacteria that are resistant to the most popular antibiotics used for tuberculosis.
How Is Delamanid Used?
The antibiotic Delamanid is used. It functions by eradicating tuberculosis-causing germs.
What Are Some Delamanid Side Effects That Are Common?
Dizziness, headache, nausea, vomiting, diarrhea, joint pain, abdominal discomfort, and muscle pain.
What Are the Criteria for Delamanid?
Fundamental Standards
The topic expert committee and the national expert committee on the regulation of novel anti-TB medications in India have accepted the following conditions for patients to receive Delamanid :
Inclusion Standards:
-
People (>18 years) who are human immunodeficiency virus, HIV-positive (PLHIV) are not eligible for a shorter MDR-TB regimen because of resistance, contraindications, or tolerability.
-
MDR/RR-TB with resistance to XDR-TB and Mixed Pattern DR-TB, which includes patients who are failing any DR-TB regimen, have drug intolerance or contraindications, or who return after interruption or the emergence of any exclusion criteria for shorter MDR-TB regimen, or who have extensive or advanced disease, as well as others who are considered to be at higher baseline risk for poor outcomes.
-
HIV+ patients (in consultation with ART (antiretroviral therapy) centers), those over 65, those with diabetes, hepatic or severe renal impairment, people with blood albumin levels below 2.8 g/dL, and people who use drugs or alcohol should exercise extra caution.
-
The NDR-TBC committee may cautiously examine Delamanid in patients with baseline blood albumin levels below 2.8 g/dL, subject to expert review. In these patients, serum albumin must be monitored quite frequently.
-
Before starting Delamanid, electrolyte imbalances (serum potassium, magnesium, and calcium) must be resolved.
-
Women should not be pregnant or should be utilizing some form of birth control. Individuals with managed stable arrhythmia can be considered after getting cardiac consultation; they should be prepared to continue using birth control techniques throughout treatment, or they must have been postmenopausal for the previous two years.
-
Lactose is present in the film-coated Delamanid pills. After consulting with a specialist, patients with uncommon hereditary issues such as glucose-galactose malabsorption, Lapp lactase deficiency, or galactose intolerance can be considered.
What Are the Certain Points to Consider While Prescribing?
Cardiac Risk Factors: Patients with the following risk factors should not begin treatment with Delamanid (Dlm) unless it is determined that the benefits outweigh the risks. During the entire course of their Dlm treatment, these patients should have their ECG monitored quite frequently.
-
Any clinical disease is known to lengthen the QTc interval or QTc > 500 ms, including known congenital QTc prolongation.
-
A history of clinically significant bradycardia or symptomatic cardiac arrhythmias.
-
Any cardiac abnormalities that increase the risk of developing an arrhythmia, such as severe hypertension, hypertrophic cardiomyopathy, or congestive heart failure with a low left ventricular ejection fraction.
-
Disturbances in electrolytes, especially hypokalaemia, hypocalcemia, or hypomagnesemia.
-
Using drugs that are known to lengthen the QTc interval. Antiarrhythmics (such as Amiodarone, Disopyramide, Dofetilide, Ibutilide, Procainamide, Quinidine, Hydroquinone, and Sotalol, among others) are among them, but they are not the only ones.
-
Antidepressants and neuroleptics (such as Phenothiazines, Sertindole, Sultopride, Chlorpromazine, Haloperidol, or Mesoridazine).
-
A few antibacterial substances include macrolides (such as Erythromycin and Clarithromycin), fluoroquinolones (such as Moxifloxacin and Sparfloxacin), triazole antifungal substances, and Saquinavir or Pentamidine.
-
A few antihistamines that do not cause drowsiness include Terfenadine, Astemizole, and Mizolastine.
-
Cisapride, Droperidol, Domperidone, Bepridil, Diphemanil, Probucol, Levomethadyl, Methadone, Vinca alkaloids, and Arsenic trioxide are some of the medications used.
-
In patients with a normal ECG (electrocardiogram) at baseline, the ECG should be examined before the treatment begins, on day 15 of treatment, and then once a month for the entire course of Dlm therapy.
-
Very regular ECG monitoring is required when there is a high risk of QTc interval prolongation, such as while using other QTc prolonging medications, having known cardiac risk factors, or treating patients with baseline ECG abnormalities on the advice of a cardiologist.
-
Treat electrolyte abnormalities that may lead to cardiotoxicity, particularly those that include serum potassium.
-
If a QTcF > 500 ms is seen, stop taking all Qtc prolonging medications.
Efforts to reduce the possibility of Dlm-resistant MTB strain formation include:
-
As advised by the WHO, Delamanid should only be used in combination regimens that are acceptable for treating MDR-TB. It should never be added to a failing regimen.
Extra-Pulmonary TB:
Although the use of these medications in EPextra pulmonary MDR-TB patients has yet to receive regulatory approval because the evidence is still developing, there is no absolute contraindication to their use if the benefits outweigh any potential risks. Dlm's effectiveness in treating central nervous system TB is still unknown.
Children and Adolescents (6 to 17 years):
Although the WHO released a temporary guideline in 2016 for the use of Delamanid in this age group with doses of 50 mg BID (twice daily) (six to11 years) and 100 mg BID (12 to 17 years) for six months (16), regulatory authorities, including India, are still in the process of approving it. Delamanid use in children and adolescents (six to 17 years old) would be taken into account once regulatory permissions for such use were secured.
When selecting alternative second-line medications, caution should be taken with baseline laboratory abnormalities. The following patients would also be taken into consideration for treatment with caution when selecting second-line medications for the regimen (DAIDS Grading) Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events:
-
Low albuminemia (2.8 g/dL or below).
-
Creatinine grade 2 or higher (>1.5 times the upper limit of normal.
-
Grade 4 hemoglobin (less than 8.0 g/dL).
-
Aspartate aminotransferase (AST) grade 2 or greater (>2.5 times upper limit of normal (ULN)); Alanine aminotransferase (ALT) grade 2 or greater (>2.5 times ULN); Total bilirubin grade 2 or larger (>1.6 times ULN); and Lipase/Amylase grade 2 (with no indications or symptoms of pancreatitis) or greater (>1.5 times ULN).
For Doctors:
Indications:
Delamanid is indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB).
Pharmacodynamics
The range of Delamanid's minimum inhibitory concentrations (MIC) against isolates of Mycobacterium TB is 0.006 to 0.024 g/mL. Delamanid shows in vitro action against M. kansasii and M. bovis among non-tuberculosis mycobacteria. Delamanid does not exhibit cross-resistance to other anti-tuberculosis medications and exhibits no in vitro efficacy against gram-negative or positive bacterial species. Delamanid has been shown to reduce M. tuberculosis colony numbers in a dose-dependent way in mouse models of chronic tuberculosis. Repeated administration of Delamanid may result in QTc-prolongation by blockage of the cardiac potassium channel (hERG channel), with the major metabolite of Delamanid primarily responsible for this action. Delamanid has been shown in animal experiments to enhance prothrombin time (PT) and activated partial thromboplastin time (APTT) while attenuating vitamin K-dependent blood coagulation.
Pharmacokinetics:
Unlike first-line anti-TB medications, which should be taken on an empty stomach, Delamanid is best given with food since food improves absorption. The peak concentration is seen four to five hours after oral ingestion. Early studies revealed that Delamanid exposure was not dose-related and reached a plateau at 300 mg. This could result from the medication's weak water solubility and restricted absorption at larger doses.
Mechanism Of Action:
Delamanid is a prodrug that must be biotransformed to exert its antimycobacterial activity against both growing and nongrowing mycobacteria. This biotransformation occurs via the mycobacterial F420 coenzyme system, which includes the deazaflavin-dependent nitroreductase (Rv3547). Five coenzymes F420 genes fgd, Rv3547, fbiA, fbiB, and fbiC have mutations that have been postulated as the mechanism of Delamanid resistance. The radical intermediate created when Delamanid and desnitro-imidazooxazole derivative react upon activation is thought to mediate antimycobacterial actions by inhibiting methoxy-mycolic and keto-mycolic acid synthesis, resulting in a reduction in the components of mycobacterial cell walls and the mycobacteria's ability to survive. It is believed that the derivative of nitroimidazooxazole produces reactive nitrogen species, such as nitrogen oxide (NO). Delamanid does not, however, affect alpha-mycolic acid as isoniazid does.
Absorption
The highest plasma concentration was 135 ng/mL following oral administration of 100 mg of Delamanid. After ten to 14 days, steady-state concentration is attained. With increasing doses, Delamanid plasma exposure rises less than proportionally. Delamanid's oral bioavailability in animal models (dog, rat, and mouse) was between 35 percent and 60 percent. Between 25 to 47 percent of the absolute oral bioavailability is thought to exist in people. Due to Delamanid's low water solubility, oral bioavailability in humans is increased with a typical meal by roughly 2.7 fold compared to fasting settings.
Volume of Distribution:
100 L is the apparent volume of distribution (Vz/F). Delamanid and/or its metabolites have been found to excrete into breast milk according to pharmacokinetic evidence in animals. The Cmax for Delamanid in breast milk was four times higher than that in blood in lactating rats.
Proteins Binding:
Delamanid has a binding affinity of 99.5 percent or higher for all plasma proteins.
Metabolism:
Delamanid primarily undergoes albumin metabolism, with some CYP3A4 involvement. Hepatic CYP1A1, CYP2D6, and, to a lesser extent, CYP2E1 may also play a role in the metabolism of Delamanid [31966]. Patients receiving Delamanid had plasma levels of four main metabolites (M1–M4), of which M1 and M3 accounted for 13 percent to 18 percent of the total plasma exposure in people.
Even if they no longer have much pharmacological efficacy, they could still cause QT prolongation. This is particularly accurate for the primary Delamanid metabolite, M1.
Serum albumin metabolizes Delamanid primarily by hydrolytically cleaving the 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole moiety to produce M1 (DM-6705). The production of this significant metabolite is considered an important starting point for the metabolism of Delamanid. Three routes are available for further catalyzing M1 (DM-6705). The oxazole moiety in DM-6705 is hydroxylated to generate M2 ((4RS,5S)-DM-6720) in the first metabolic route. Oxidation of the hydroxyl group and tautomerization of the oxazole to M3 ((S)-DM-6718), an imino-ketone metabolite, are then carried out by CYP3A. In the second metabolic route, the oxazole amine is hydrolyzed and deaminated to produce M4 (DM-6704) before being hydroxylated to produce M6 ((4R,5S)-DM-6721) and M7 ((4S,5S)-DM-6722), and finally being oxidized to produce M8 ((S)-DM-6717), another ketone metabolite. The third mechanism is the hydrolytic breakage of the oxazole ring to produce M5 (DM-6706).
Route of Elimination:
Less than 5 percent of Delamanid is eliminated in the urine, most of which is in the feces.
Half-Life:
The half-life is between 30 and 80 hours.
Toxicity:
Although Delamanid overdoses have not occurred, some adverse events have been reported more frequently, and the risk of QT prolongation has increased in a dose-related way. In the event of an overdose, supportive treatment as needed and prompt steps to eliminate Delamanid from the digestive system should be taken. ECG monitoring should be done frequently.
No substantial effects on people have been found in genotoxicity and carcinogenic potential studies. By blocking hERG potassium channels, Delamanid and/or its metabolites can potentially alter cardiac repolarization. Although the clinical importance of this discovery has not been proven, foamy macrophages were seen in the lymphoid tissue of several organs during repeat-dose investigations in dogs. Delamanid and/or its metabolites impede vitamin K synthesis, inhibiting clotting factors II, VII, IX, and X, according to studies on the toxicity of repeated doses in rabbits. In rabbit reproduction experiments, embryo-fetal damage was reported at maternally hazardous doses.
Drug Interaction:
-
Abametapir: Combining Delamanid and Abametapir can raise the serum levels of Delamanid.
-
Acebutolol: Acebutolol may make Delamanid's ability to prolong QTc more pronounced.
-
Acrivastine: Acrivastine may make Delamanid more active in lengthening QTc.
-
Adagrasib: Adagrasib may increase Delamanid's ability to extend QTc.
-
Adenosine: Delamanid's ability to extend QTc may be enhanced by Adenosine.
-
Ajmaline: Ajmaline might make Delamanid more effective at lengthening QTc.
-
Alfuzosin: Alfuzosin may make Delamanid more effective at lengthening QTc.
-
Alimemazine: Delamanid's capacity to extend QTc may be increased by Alimemazine.
-
Amantadine: Delamanid's ability to extend QTc may be enhanced by Amantadine.
-
Amifampridine: Delamanid's capacity to extend QTc may be increased by Amifampridine.
Adverse Effects:
The treatment group was shown to have a considerably greater frequency of QT prolongation compared to the placebo group. Given that it occurred more frequently in the 200 mg BD/day group than in the 100 mg BD/day group, it was determined that this effect was dose-dependent. Yet it was just mildly to moderately severe, and arrhythmia and syncope symptoms were absent. No other severe treatment-emergent side events have been seen in the clinical studies.
Present Situation:
EMA has given Delamanid a conditional marketing license. It should be used in adult patients with pulmonary MDR-TB who cannot take the currently approved regimen because of resistance or intolerance as a component of a suitable combination regimen.
Advantages and Limitations:
The advantages of Delamanid will be useful in lowering the length of treatment and risk of toxicity in MDR-TB due to its high potency action, low possibility of drug-drug interactions, better toxicity profile, and post-antibiotic activity against intracellular bacilli. Future research should focus on long-term clinical trials on safety and efficacy, interactions with existing and novel anti-TB drugs, pharmacokinetic studies in specialized populations, and investigations on medication administration with food.
What Do Bedaquiline and Delamanid Combine to Form?
Since 2016, case studies and case series have been published on the use of Bedaquiline and Delamanid together as a last resort therapy for patients with limited other therapeutic alternatives. The key issue with a regimen involving the combination of Bedaquiline and Delamanid would still be the theoretical safety profile due to the possibility of QT interval prolongation effects of both medications, which is why the WHO has not yet advised their combined usage. Despite the lack of published prospective research, recent observational investigations yielded encouraging initial findings.
In 2017, three case series reported that of 12 patients treated concurrently with Bedaquiline and Delamanid, 5 (41.7 percent) patients had prolongation of the QT interval corrected with Fridericia's formula (QTcF) of greater than 500 ms, but no arrhythmias were observed. This was in contrast to 3.2 percent (42/1301) of patients who received Bedaquiline alone. In 2018, the largest cohort research revealed that none of the 28 actively monitored patients experienced episodes of QTcF values greater than 500 ms or cardiac arrhythmias. Nonetheless, close electrocardiograph monitoring is still required.
Conclusion:
The confidence in treating drug-resistant TB has increased as a result of recent approvals for anti-TB medications like Bedaquiline and Delamanid. Delamanid may be a significant treatment option for MDR-TB, XDR-TB, and TB in HIV-positive patients due to its favorable characteristics of strong efficacy, minimal toxicity, and lack of interaction with antiretroviral medications.
